Invention Grant
- Patent Title: Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
-
Application No.: US15577369Application Date: 2016-05-26
-
Publication No.: US10751412B2Publication Date: 2020-08-25
- Inventor: Ying Yu , Andrew Evan Denker , Svetlana Sadekova , Uyen Truong Phan , Robert A. Kastelein , David Ross Kaufman , Robert L. Coffman , Cristiana Guiducci , Robert S. Janssen
- Applicant: MERCK SHARP & DOHME CORP. , DYNAVAX TECHNOLOGIES CORPORATION
- Applicant Address: US NJ Rahway US CA Emeryville
- Assignee: MERCK SHARP & DOHME CORP.,DYNAVAX TECHNOLOGIES CORPORATION
- Current Assignee: MERCK SHARP & DOHME CORP.,DYNAVAX TECHNOLOGIES CORPORATION
- Current Assignee Address: US NJ Rahway US CA Emeryville
- Agency: Faegre Drinker Biddle & Reath LLP
- International Application: PCT/US2016/034275 WO 20160526
- International Announcement: WO2016/196173 WO 20161208
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61K45/06 ; A61K31/7115 ; C07K14/435 ; A61K39/39 ; C07K16/28 ; C07K16/24 ; A61P35/00 ; A61K39/00
Abstract:
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
Public/Granted literature
- US20180169229A1 COMBINATION OF A PD-1 ANTAGONIST AND CPG-C TYPE OLIGONUCLEOTIDE FOR TREATING CANCER Public/Granted day:2018-06-21
Information query
